Clinical Trial Update: Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing tigecycline to ceftriaxone for complicated intra-abdominal infection and community-acquired pneumonia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Complicated Intra-abdominal Infection

Drugs mentioned

• ceftriaxone (brand: Rocephin) (ceftriaxone)
• tigecycline (brand: Tygacil) (tigecycline)

Snippet

Sponsor: Pfizer | Conditions: Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection | Phase 3 | Status: WITHDRAWN